CXCL12

Cellenkos® enters into Sponsored Research Agreement with Icahn School of Medicine at Mount Sinai, New York.

Retrieved on: 
Monday, April 1, 2024
Research, Pacritinib, JAK2, Bone marrow, Blood transfusion, CXCR4, Inflammation, Patient, University, Ruxolitinib, Clinical trial, CXCL12, Fedratinib, Safety, Pancreatic serous cystadenoma, University of California, Davis, MD Anderson Cancer Center, Albert Einstein Israelite Hospital, Pharmaceutical industry

Research exploring CK0804 (CXCR4-enriched, allogeneic, cord blood-derived T-regulatory cells) for treatment of myelofibrosis patients.

Key Points: 
  • Research exploring CK0804 (CXCR4-enriched, allogeneic, cord blood-derived T-regulatory cells) for treatment of myelofibrosis patients.
  • This research will be conducted under the guidance of Ronald Hoffman, MD, Albert A. and Vera G. List Professor of Medicine and Director of the Myeloproliferative Disorders Research Program at The Tisch Cancer Institute- Mount Sinai.
  • CK0804 is a novel allogeneic, CXCR4 enriched, Treg cell therapy product that utilizes Cellenkos' proprietary CRANE® technology to generate disease specific products.
  • Dr. Ronald Hoffman serves as a paid consultant for Cellenkos.

Cellenkos® Announces Oral Presentation and Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition

Retrieved on: 
Monday, November 6, 2023
Primary myelofibrosis, Life, Bone marrow, Inflammation, CXCR4, Ruxolitinib, Cell, CXCR5, Society, ASH, Suboptimal health, CD39, Anemia, Blood transfusion, Exposition, Safety, CD73, CXCL12, Patient, CD62L, Pharmaceutical industry, Rare-earth element, Regulatory T cell

Oral presentation highlights the resolving of inflammation and superior homing to bone marrow of CXCR4-enriched T regulatory cells.

Key Points: 
  • Oral presentation highlights the resolving of inflammation and superior homing to bone marrow of CXCR4-enriched T regulatory cells.
  • HOUSTON, Nov. 6, 2023 /PRNewswire/ -- Cellenkos® Inc., a clinical stage biotechnology company focused on developing allogeneic, off-the-shelf, T regulatory (Treg) cell therapies for treatment of rare inflammatory diseases and autoimmune disorders, today announces an oral presentation and poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which is being held December 9-12, 2023, in San Diego, California.
  • This presentation has also been selected for ASH Abstract Achievement Award.
  • The poster presentation will elaborate on the results of Company's CK0804 Phase 1b trial.

Nitrase Therapeutics Announces Publication in the Journal of Biological Chemistry on the Role of Tyrosine Nitration in Cell Signaling and Cancer Biology

Retrieved on: 
Thursday, July 13, 2023
DAMP, Biochemistry, Database, Nitration, STAT1, Tyrosine, Phosphorylation, HER2, Hsps, CCL2, Bioorganic chemistry, Enzyme, Cancer, CXCL12, Sirtuin 2, LCK, Human, SHP2, DSM-IV codes, BCL2, Protein, Journal, B cell, HDAC2, Cell, Drug discovery, JAK2, Histone deacetylase 2, Sirtuin 6, Therapy, Janus kinase 2, SIRT6, SIRT2, Medical imaging

Nitration and phosphorylation overlapped in 879 tyrosine residues in 460 proteins.

Key Points: 
  • Nitration and phosphorylation overlapped in 879 tyrosine residues in 460 proteins.
  • The analysis revealed three major cellular networks that could be impacted by tyrosine nitration, resulting in altered protein function, localization, turnover, and protein-protein interactions.
  • Known sites of tyrosine nitration are also sites of phosphorylation, suggesting an extensive role for nitration in cell signaling, such that tyrosine nitration could profoundly interfere or alternatively complement tyrosine phosphorylation.
  • Tyrosine nitration is associated with different types of cancer by altering metabolic reprogramming and signaling.

Equillium Announces Three Poster Presentations at the Annual Meeting of The American Association of Immunologists

Retrieved on: 
Monday, May 9, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Degenerative disease, Cytokine, Forward-looking statement, Population, FOXP3, Oregon Convention Center, Private Securities Litigation Reform Act, Immune system, Ulcerative colitis, Volunteering, Nasdaq, Autoimmunity, Multiple sclerosis, Alopecia areata, Itolizumab, Safety, CD6, CD14, Patient, Trial of the century, Partnership, Association, Risk, Inflammatory bowel disease, T helper 17 cell, American Association, CD8, Therapy, EQUIP, Movement, Come Reap, EDGAR, SEC, Feedback, CXCL12, Inflammation, Cell, Journal of Immunology, Pharmaceutical industry, Vaccine, Sales

Collectively, these presentations suggest that the CD6-ALCAM pathway is an attractive target for autoimmune and inflammatory diseases and that itolizumab may be ideally suited to target this pathway.

Key Points: 
  • Collectively, these presentations suggest that the CD6-ALCAM pathway is an attractive target for autoimmune and inflammatory diseases and that itolizumab may be ideally suited to target this pathway.
  • Key Highlights, Summary and Conclusions from Presentation:
    First study to directly characterize the role of CD6 in the development and activity of T regulatory cells.
  • T regulatory cells derived from CD6 low cells had greater co-expression of FOXP3 and HELIOS (~2-fold) vs. T regulatory cells derived from isotype-treated CD6 high cells.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.

Equillium Announces Three Poster Presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTR

Retrieved on: 
Monday, April 25, 2022
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, Society, Irritation, EDGAR, Feedback, HSCT, Transplant, Nausea, Pharmacokinetics, Adult, Alopecia areata, Semipermeable membrane, Center, Rash, Private Securities Litigation Reform Act, Serum, Center for International Blood and Marrow Transplant Research, CXCL12, Steroid, Risk, Patient, GVHD, NCT, Jaundice, Skin discoloration, TEM, Mortality, Trial of the century, Nasdaq, Itch, CD6, SEC, Forward-looking statement, EQUIP, Safety, McMillan, Disease, Partnership, Vomiting, Diarrhea, Salt Palace, Therapy, Association, Cancer, Research, Pharmaceutical industry, Vaccine, Dietary supplement, Sales, Degenerative disease, Efficacy, Itolizumab

The hybrid meetings are taking place virtually and in-person at the Salt Palace Convention Center in Salt Lake City, April 23 26, 2022.

Key Points: 
  • The hybrid meetings are taking place virtually and in-person at the Salt Palace Convention Center in Salt Lake City, April 23 26, 2022.
  • Symptoms of GVHD include rash, itching, skin discoloration, nausea, vomiting, diarrhea, and jaundice, as well as eye dryness and irritation.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.
  • Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

AIM ImmunoTech Announces Positive Data from Phase 1 Study Evaluating Ampligen® for the Treatment of Stage 4 Metastatic Triple Negative Breast Cancer

Retrieved on: 
Monday, April 11, 2022
UPMC, Private Securities Litigation Reform Act, Company, Cancer, FOXP3, PSLRA, Celecoxib, Therapy, The I.V. Stalin White Sea – Baltic Sea Canal, CCL5, NYSE, Triple-negative breast cancer, CXCL10, Survival, AACR, Doctor of Philosophy, Research, American Association, Metastasis, Neoplasm, GZMB, American, Ovarian cancer, AIM ImmunoTech, Immunology, Association, American Association for Cancer Research, COVID-19, CTL, GLOBE, Degenerative disease, CKM, AIM, Lists of diseases, Breast cancer, CCL22, CXCL12, Patient, Disease, Pembrolizumab, Medical imaging, Pharmaceutical industry, Medical device, Vaccine, Dietary supplement, Regulatory T cell, Roswell Park Comprehensive Cancer Center, TME, Rintatolimod, MD

OCALA, Fla., April 11, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced the presentation of positive data from a Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple-negative breast cancer using chemokine modulation therapy, including AIM ImmunoTech Inc.’s drug candidate, Ampligen® (also known as rintatolimod), interferonα-2b, and pembrolizumab at the American Association for Cancer Research (AACR) Annual Meeting 2022, being held April 8-13, 2022, in New Orleans, Louisiana.

Key Points: 
  • In the study, six evaluable patients (33-75 years) with mTNBC received 6 doses of Ampligen (200 mg i.v.
  • Three patients had stable disease lasting 2.4, 2.5 and 3.8 months, as of data cut off September 1, 2021.
  • An additional patient (non-evaluable) had a partial response (breast tumor autoamputation) with massive tumor necrosis in the post-CKM biopsy.
  • Significant additional testing and trials will be required to determine whether Ampligen will be an effective treatment of Stage 4 metastatic triple negative breast cancer or otherwise, and no assurance can be given that this will be the case.

Pushing past pancreatic tumors' defenses

Retrieved on: 
Wednesday, February 16, 2022
National academy, Patient, Technology, Cancer, TGM2, Laboratory, Science, SPRING, Education, University of Science and Technology of China, KRT19, Immune system, Pancreatic cancer, Breast, Pancreatic tumor, Cold Spring Harbor Laboratory, CXCL12, Student, Neoplasm, Nobel Prize, Protein, Neuroscience, Deleted in Colorectal Cancer, Research, Multimedia, Wang, University, Biomedical Research, Trial of the century, Vaccine, Pharmaceutical industry

Cancer cells weave a deactivating signal into a protective coat of armor that excludes T cells that would otherwise kill them.

Key Points: 
  • Cancer cells weave a deactivating signal into a protective coat of armor that excludes T cells that would otherwise kill them.
  • This immune deactivation pathway offers a promising new therapeutic approach for pancreatic, breast, and colorectal cancers.
  • The scientists used genetic editing to turn off the production of KRT19 or TGM2 in mouse pancreatic tumors.
  • In a previous small clinical study of pancreatic cancer patients, Fearon and collaborators showed that the drug plerixafor (a CXCL12 receptor blocker) increased the infiltration of T cells into patients' pancreatic tumor tissues.

X4 Pharmaceuticals Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to Treat Patients with Double-Mutation Waldenström’s Macroglobulinemia

Retrieved on: 
Saturday, December 11, 2021
Diagnosis, WHIM syndrome, Security (finance), Cancer, Harvard Medical School, Risk, Research, BTK, Private Securities Litigation Reform Act, FRCP, B-cell lymphoma, Biology, Cohort study, Mutation, Clinical trial, Lymphoma, White blood cell, SCN, ASH, Gram, CXCL12, GLOBE, FACP, Safety, Pids, Society, PID, Immunoglobulin M, Macroglobulinemia, Patient, COVID-19, Immunodeficiency, Forward-looking statement, CXCR4, MYD88, Medication, Ageing, U.S. Securities and Exchange Commission, Therapy, Progression-free survival, Pharmacokinetics, Dana–Farber Cancer Institute, Â, Poster, SEC, ORR, Pharmaceutical industry, Fine chemical

BOSTON, Dec. 11, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with immune system dysfunction, today announced new positive efficacy and safety data from the ongoing Phase 1b clinical trial of its lead candidate mavorixafor, in combination with ibrutinib, for patients with Waldenström’s macroglobulinemia (WM) and confirmed MYD88 and CXCR4 mutations. These study results were reported today in a poster presentation at the American Society of Hematology (ASH) Annual Meeting, taking place both virtually and in person in Atlanta, GA, December 11-14, 2021.

Key Points: 
  • Overall, the combination of mavorixafor and ibrutinib was tolerated with a manageable safety profile at the low- and mid-level dosing of mavorixafor; dose escalation to 600 mg mavorixafor is ongoing.
  • X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company leading the discovery and development of novel therapeutics to benefit people with immune system dysfunction.
  • Mavorixafor has already demonstrated clinical potential in a Phase 2 trial in people with WHIM syndrome, a rare PID.
  • Forward-looking statements include, without limitation, statements regarding the clinical development and therapeutic potential of mavorixafor and the advancement of X4s pipeline.

NOXXON Summarizes Essential Points From Key Opinion Leader Event on NOX-A12 & Radiotherapy Combination in Brain Cancer Held on November 23, 2021 With Dr Frank A. Giordano

Retrieved on: 
Thursday, December 2, 2021
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Patient, GLORIA, Pakistan Society of Neuro-Oncology, Pancreatic cancer, Safety, Brain, CEO, Temozolomide, Cell, CXCL12, Merck Sharp & Dohme Federal Credit Union, NOX-A12, GBM, Population, MGMT, Cancer, Recurrence, Radiation, Radiation therapy, Tumor microenvironment, Giordano, KOL, NOX, Department, Prognosis, Pembrolizumab, SD, Research, Survival, TME, ESMO, Neoplasm, Communication, Adult, PR, Terminology, SNO, OLA, Society, Immune system, MOS, Disease, University Hospital Bonn, Standard of care, Teaching hospital, Pharmaceutical industry, Medical device, Medical imaging, NOXXON, the GLORIA Study, the OPTIMUS Study, NOXXON, THE GLORIA STUDY, THE OPTIMUS STUDY

on November 23, 2021, to discuss the combination of NOX-A12 and radiotherapy in brain cancer (glioblastoma, GBM).

Key Points: 
  • on November 23, 2021, to discuss the combination of NOX-A12 and radiotherapy in brain cancer (glioblastoma, GBM).
  • Dr. Giordano is a research pioneer and expert in precision radiation therapy and intraoperative irradiation of malignant tumors.
  • During the KOL event, Dr. Giordano emphasized several other important points, summarized in the Annex to this press release.
  • Key messages from the KOL event on NOX-A12 and radiotherapy combination in brain cancer held on November 23, 2021 with Dr. Frank.

NOXXON: New Phase 1/2 Data On NOX-A12 & Radiotherapy Combination in Brain Cancer Presented at the Society for Neuro-Oncology Annual Meeting 2021

Retrieved on: 
Monday, November 22, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Other Health, Patient, GLORIA, Pakistan Society of Neuro-Oncology, CXCL12, NOX-A12, GBM, MGMT, Radiation, Radiation therapy, Tumor microenvironment, Department, Glioblastoma, Society, TME, SNO, Brain, University Hospital Bonn, Teaching hospital, Medical imaging, Pharmaceutical industry, NOXXON, the GLORIA Study, the OPTIMUS Study, NOXXON, THE GLORIA STUDY, THE OPTIMUS STUDY

Interestingly and very importantly, such benefits were observed across all available tumor tissue and not only in small subsections.

Key Points: 
  • Interestingly and very importantly, such benefits were observed across all available tumor tissue and not only in small subsections.
  • The data presented by Dr. Giordano at the SNO meeting are a significant step forward in bringing NOX-A12 to glioblastoma patients.
  • NOXXON is also studying NOX-A12 in brain cancer in combination with radiotherapy which has been granted orphan drug status in the US and EU for the treatment of certain brain cancers.
  • The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments.